LightNews LightNews
jamesthethird.bsky.social
@jamesthethird.bsky.social
9 followers 32 following 0 posts
Posts Replies Media Videos
Reposted
erictopol.bsky.social
New report that CHIP (clonal hematopoiesis of indeterminate potential, blood stem cell clones that increase with age) is an independent risk factor for myocarditis and pericarditis, promoting inflammation #ESC2025
@jama.com

jamanetwork.com/journals/jam...
August 30, 2025 at 3:40 PM
Reposted
raajitrampal.bsky.social
Out today in
@NatureMedicine
phase 3 data from thh MANIFEST-2 study nature.com/articles/s41...
@aarongerds.bsky.social @mpndoc.bsky.social @kuykendallmd.bsky.social @rubenmesamd.bsky.social
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial - Nature Medicine
In a randomized phase 3 trial, the combination of the BET inhibitor pelabresib with the JAK inhibitor ruxolitinib resulted in a significantly higher spleen volume reduction from baseline versus placeb...
nature.com
March 10, 2025 at 7:36 PM
Reposted
nicogagelmann.bsky.social
🎉Finally published🎉

Clearance of driver mutations after transplantation for myelofibrosis

@nejm.org

www.nejm.org/doi/full/10....
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...
www.nejm.org
January 9, 2025 at 11:05 AM